Gregory Fiore, M.D., President and CEO of Exacis, and member of Eterna’s Board of Directors, commented, “Exacis was started with the goals of improving patient outcomes and experiences as well as increasing access to life-saving treatments. Today’s announcement marks a key milestone on the path to achieving these goals. The Eterna Board and leadership are committed to and have been working toward these same goals, and we believe that this acquisition provides Eterna with the tools required to develop next-generation therapies targeting indications of high unmet need, including blood cancers and solid tumors.”
